 Article
|
|
|
|
Services
|
|
|
|
Google Scholar
|
|
|
|
Social Bookmarking
|
|
|
|
PubMed
|
|
Articles in PubMed by Author:
|
 |
PubMed
|  |
|
|
LETTER
Blood Alcohol Levels after Prolonged Histamine-2-Receptor Antagonist Treatment
Alessandro Cassini, MD;
Franceso Mari, PhD; and
Calogero Surrenti, MD
1 January 1994 | Volume 120 Issue 1 | Page 90
TO THE EDITOR:
Recent studies indicate that cimetidine and ranitidine, but not famotidine, may inhibit gastric alcohol-dehydrogenase activity, thus impairing the gastric first-pass metabolism of ethanol [1-4]. Those studies, however, were done in "artificial" conditions (healthy patients; 1 week of treatment; last dose at breakfast, 1 hour before alcohol ingestion). We studied whether prolonged treatment with ranitidine or famotidine affected blood alcohol concentrations in 16 men with duodenal ulcers. Patients with Helicobacter pylori-associated duodenal ulcers were not enrolled [5]. Patients were randomly assigned to receive either 300 mg of ranitidine (n = 8) or 40 mg of famotidine (n = 8) at bedtime for 2 months. The rate of gastric first-pass metabolism was checked in all patients before study entry and was found to be 53% by comparing the area under the curve (AUC) of blood alcohol concentration after either intravenous or oral administration of 0.3 g/kg of ethanol (AUC [intravenous] = 11.6 ±1.6 mM/h; AUC [oral] = 5.4 ±0.6 mM/h). Patients had a standard lunch (at 1:00 p.m.), and 0.3 g/kg of alcohol was consumed 15 minutes after the meal. Blood alcohol concentrations were measured by a gas-chromatographic procedure up to 150 minutes after drinking alcohol. Ranitidine did not significantly modify either the mean oral AUC (5.8 ±1.8 mM/h before treatment compared with 6.2 ±1.4 mM/h after treatment) or the peak blood alcohol concentration (4.6 ±1.1 mM compared with 5.3 ±1.7 mM) after 2 months of treatment. Famotidine failed to affect blood alcohol concentration in the second group of patients (AUC [oral] = 5.0 ±1.4 mM/h compared with 5.6 mM/h ±1.7 mM/h, peak blood alcohol concentration = 4.0 mM ±1.7 mM compared with 4.3 mM ±1.8 mM; before and after treatment, respectively). No significant differences in alcohol-dehydrogenase activity were found in the gastric mucosal biopsy specimens of patients after treatment with either drug. Although ranitidine and some other histamine-2-receptor antagonists have been clearly shown to inhibit gastric alcohol-dehydrogenase activity in vitro, our results suggest that these studies may not be clinically relevant.
|
Author and Article Information
|
|---|
Universita di Firenze; Firenze, Italy
1. Julkunen RJ, DiPadova C, Lieber CS. First pass metabolism of ethanol: a gastrointestinal barrier against the systemic toxicity of ethanol. Life Sci. 1985; 37:567-73.
2. Hernandez-Mugnoz R, Caballeria J, Baraona E, Uppal R, Greenstein R, Lieber CS. Human gastric alcohol dehydrogenase: its inhibition by H2-receptor antagonists, and its effect on the bioavailability of ethanol. Alcohol Clin Exp Res. 1990; 14:946-50.
3. Caballeria J, Baraona E, Deulofeu R, Hernandez-Munoz R, Rodes J, Lieber CS. Effects of H2-receptor antagonists on gastric alcohol dehydrogenase activity. Dig Dis Sci. 1991; 36:1673-9.
4. DiPadova C, Roine R, Frezza M, Gentry RT, Baraona E, Lieber CS. Effects of ranitidine on blood alcohol levels after ethanol ingestion. JAMA. 1992; 267:83-6.
5. Roine R, Salmela KS, Hook-Nikanne J, Kosunen TU, Salaspuro M. Alcohol dehydrogenase mediated acetaldehyde production by Helicobacter pylori. A possible mechanism behind gastric injury. Life Sci. 1992; 51:1333-7.
About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Hou, E. Horney, D. Stockelberg, S. Jacobsson, J. Kutti, and H. Wadenvik
Multiple Quinine-Dependent Antibodies in a Patient With Episodic Thrombocytopenia, Neutropenia, Lymphocytopenia, and Granulomatous Hepatitis
Blood,
December 15, 1997;
90(12):
4806 - 4811.
[Abstract]
[Full Text]
[PDF]
|
|
|
Top
Author & Article Info
References